ResearcherUniversity of MissouriNo recent work listed
Jussuf T. Kaifi
Matched on ORCID iD 0000-0003-3425-2356; OpenAlex author ID A5065897181. Sources: ClinicalTrials.gov.
Their work
- Papers
- 6
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2011: 2 papers · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 trial · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper
Papers 6
- Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Co-author DOI 10.1016/j.tranon.2021.101262↗
- LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.3389/fcell.2021.647387↗
- Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Co-author DOI 10.1016/j.canlet.2019.04.022↗
- Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2488-7↗
- Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.21957↗
- Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? Co-author DOI 10.1007/s11605-011-1469-y↗
Trials 1
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Guangfu Li · 3 shared papers, 2019–2022 · strength 0.35
- Paper Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. DOI 10.1016/j.tranon.2021.101262↗
- Paper LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. DOI 10.3389/fcell.2021.647387↗
- Paper Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. DOI 10.1016/j.canlet.2019.04.022↗
- Eric T. Kimchi · 3 shared papers, 2014–2022 · strength 0.31
- Paper Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. DOI 10.1016/j.tranon.2021.101262↗
- Paper LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. DOI 10.3389/fcell.2021.647387↗
- Paper Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic ca… DOI 10.1007/s00280-014-2488-7↗
- Hao Yuan · 2 shared papers, 2019–2021 · strength 0.20
- Xinjian Liu · 2 shared papers, 2019–2021 · strength 0.20
- Yi Miao · 2 shared papers, 2019–2021 · strength 0.20
- Chiswili Yves Chabu · 1 shared paper, 2022 · strength 0.15
- Jing Zhou · 1 shared paper, 2022 · strength 0.15
- Kun Cheng · 1 shared paper, 2021 · strength 0.11
- Kuirong Jiang · 1 shared paper, 2021 · strength 0.11
- Min Li · 1 shared paper, 2019 · strength 0.09
- Kuirong Jiang · 1 shared paper, 2019 · strength 0.09
- Florian Gebauer · 2 shared papers, 2011 · strength 0.06
- Michael Tachezy · 2 shared papers, 2011 · strength 0.06
- Maximilian Bockhorn · 2 shared papers, 2011 · strength 0.06
- Jakob Robert Izbicki · 2 shared papers, 2011 · strength 0.06
- Chandra Prakash Belani · 1 shared paper, 2014 · strength 0.04
- Yixing Jiang · 1 shared paper, 2014 · strength 0.04
- Niraj Jaysukh Gusani · 1 shared paper, 2014 · strength 0.04
- Yogesh Kumar Vashist · 1 shared paper, 2011 · strength 0.03
- Katharina E. Effenberger · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.